Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS: ANTH · Delayed Price · USD
0.0000
-0.0001 (-99.00%)
Apr 24, 2024, 3:50 PM EDT - Market closed
Market Cap 6.18K
Revenue n/a
Net Income n/a
Shares Out 6.18B
EPS -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 150
Open n/a
Previous Close 0.0001
Day's Range n/a
52-Week Range n/a
Beta -118.87
Analysts n/a
Price Target n/a
Earnings Date May 15, 2018

About ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 2010
Employees 21
Stock Exchange OTCMKTS
Ticker Symbol ANTH
Full Company Profile

Financial Performance

Financial Statements

News

AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which ...

3 years ago - Business Wire

AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged followi...

3 years ago - Business Wire